Respiratory Syncytial Virus Prevention In Infants: Maternal Vaccination, Long-Acting Monoclonal Antibodies, And Equity Of Access
Adolescência e Saúde · 10.06.2026 · 21 (3s) · 665-671
DOI: 10.67440/ahj.v21i3s.1083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Adolescência e Saúde, online erschienen am 10.06.2026. Verfasst von Amani Abdalla Mohammed Elawad und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
RSV is a major cause of acute lower respiratory tract infection, hospitalization, and infant mortality, particularly during the first months of life.
Objectives
To review the current strategies to prevent respiratory syncytial virus (RSV) infection in infants that include maternal vaccination and long-acting monoclonal antibodies with equity of access. Methodology: A narrative review of key selected clinical trials was conducted, mostly published in the 2020-2026 range, recommendations by WHO, guidance by the Advisory Committee on Immunization Practices and related public health literature.
Results
RSV is associated with substantial incidence of ALRI-related hospitalization and death in young infants and is more frequent in low- and middle-income countries. Maternal immunization with perfusion F protein vaccine can confer passive protection, through transplacental transfer of antibody, during the initial months of life. Monoclonal antibodies against RSV, such as nirsevimab and clesrovimab, provide direct passive protection to infants who are at a high risk of developing RSV infection, particularly in cases where their mothers were either unvaccinated, vaccinated too close to delivery, or have had impaired antibody transfer to the infant.
Conclusion
Recent advancements have changed the RSV prevention strategy for infants from support care into immunization. Today's biggest challenge is not proving scientific feasibility, but ensuring fair and effective delivery. Nations must devise context-specific strategies to integrate maternal vaccination, monoclonal antibodies in infants, surveillance, financing, and equity monitoring to shield all infants, particularly those at highest risk.
Zitieren
APA
Elawad, A. A. M., & Mustafa, A. M. A. (2026). Respiratory Syncytial Virus Prevention In Infants: Maternal Vaccination, Long-Acting Monoclonal Antibodies, And Equity Of Access. Adolescência e Saúde, 21(3s), 665-671. https://doi.org/10.67440/ahj.v21i3s.1083
Vancouver
Elawad AAM, Mustafa AMA. Respiratory Syncytial Virus Prevention In Infants: Maternal Vaccination, Long-Acting Monoclonal Antibodies, And Equity Of Access. Adolescência e Saúde. 2026;21(3s):665-671. doi:10.67440/ahj.v21i3s.1083
BibTeX
@article{Elawad2026,
author = {Elawad, Amani Abdalla Mohammed and Mustafa, Amna Mohammed Ali},
title = {Respiratory Syncytial Virus Prevention In Infants: Maternal Vaccination, Long-Acting Monoclonal Antibodies, And Equity Of Access},
journal = {Adolescência e Saúde},
year = {2026},
volume = {21},
number = {3s},
pages = {665--671},
doi = {10.67440/ahj.v21i3s.1083}
}
EUVIMED